Disclosures for "SYT-510, the Clinical Candidate of First-in-class Selective Endocannabinoid Reuptake Inhibitors, Demonstrated Efficacy in Preclinical Models of Anxiety, Spasticity, Seizure, Pain and Neuroinflammation"
-
Prof. Chicca has received personal compensation for serving as an employee of Synendos Therapeutics. Prof. Chicca has or had stock in Synendos Therapeutics.
-
Inés Reynoso-Moreno has nothing to disclose.
-
Dr. Maeder has received personal compensation for serving as an employee of Synendos Therapeutics AG.
-
Dr. lalanne has received personal compensation for serving as an employee of EphyX Neuroscience.
-
Mr. Quinones Olvera has received intellectual property interests from a discovery or technology relating to health care.
-
Mrs. Glasmacher has received personal compensation for serving as an employee of Synendos Therapeutics AG.
-
Prof. Gertsch has received intellectual property interests from a discovery or technology relating to health care.